

MediKredit NAPPI Changes and Information

Circular Number: N030/2019
Circular Date: 28 November 2019
Effective Date: 11 October 2019



Important Notice

VOLUNTARY WITHDRAWAL OF PRODUCTS: (Ultak tablets)

Please note that Cipla Medpro (Pty) Ltd in agreement with the South African Health Products Regulatory Authority (SAHPRA) issued a recall of all batches of Ultak tablets as per the table below:

| NAPPI CODE | PRODUCT (Including Strength & Form) |
|------------|-------------------------------------|
| 867934 | Ultak 150 mg tablets |
| 867942 | Ultak 300 mg tablets |

NAPPI codes for these products have been discontinued and are not claimable.

Providers should immediately return all affected batches to their supply wholesaler/distributor for full credit.

For any further information and information on stock withdrawal please contact Cipla Medpro (Pty) Ltd on 021 556 6997

Please note that Ultak has been loaded as an exclusion on all MediKredit options. Please refer your patients to their practitioners.

MediKredit Integrated Healthcare Solutions (Pty) Ltd

Head Office:
Johannesburg
10 Kikuyu Road, Sunninghill,
Sandton, 2157
P.O. Box 521058, Saxonwold, 2132



Johannesburg
Tel: Telkom: +27 (0) 11 770-6000
Call Centre: +27 (0) 860-932-273

www.medikredit.co.za